ClinVar Miner

Submissions for variant NM_000057.4(BLM):c.1968dup (p.Lys657fs) (rs772785079)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000586500 SCV000694475 pathogenic Bloom syndrome 2019-12-01 criteria provided, single submitter clinical testing Variant summary: BLM c.1968dupG (p.Lys657GlufsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.2e-05 in 251206 control chromosomes. c.1968dupG has been reported in the literature in at-least one homozygous individual born to consanguineous parents, affected with Bloom Syndrome and included in the Bloom syndrome registry (German_2007). It has subsequently been cited as a pathogenic variant in reports of carrier screening for BLM syndrome (Perreault-Micale_2015) and other literature (de Voer_2015, Salah_2014). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The variant has been observed at-least twice among individuals undergoing carrier screening at our laboratory. No other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was re-classified as pathogenic.
Ambry Genetics RCV001013870 SCV001174506 pathogenic Hereditary cancer-predisposing syndrome 2019-06-07 criteria provided, single submitter clinical testing The c.1968dupG pathogenic mutation, located in coding exon 7 of the BLM gene, results from a duplication of G at nucleotide position 1968, causing a translational frameshift with a predicted alternate stop codon (p.K657Efs*5). This alteration has been reported in a cohort of 134 persons with Bloom syndrome (BS) from the Bloom's Syndrome Registry (German J et al. Hum. Mutat., 2007 Aug;28:743-53). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000586500 SCV001209121 pathogenic Bloom syndrome 2020-07-07 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Lys657Glufs*5) in the BLM gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs772785079, ExAC 0.001%). This variant has been observed in an individual affected with Bloom syndrome (PMID: 17407155). ClinVar contains an entry for this variant (Variation ID: 495425). Loss-of-function variants in BLM are known to be pathogenic (PMID: 17407155). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000586500 SCV001132141 likely pathogenic Bloom syndrome 2015-03-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.